$1.40
0.053.7%
Last update: Nov 12, 4:22 PM
Chemomab Therapeutics Ltd
CMMBNASDAQ
Chemomab Therapeutics fell 49.4% from $2.67 to $1.35, behind the S&P 500's +10.8%. Its worst day was Jul 8 (−28.9%), and its low came Oct 26 at $1.00.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.28 missed the $-0.10 estimate on $0.00 revenue.
−10.0% · S&P 500 −1.5%
Chemomab Therapeutics shares rose 20.0%, while the S&P 500 fell 0.5%.
Story events cover the past 12 months · Times ET
+20.0% · S&P 500 −0.5%
EPS of $-0.24 missed the $-0.10 estimate on $0.00 revenue.
−3.5% · S&P 500 −0.5%
EPS of $-0.24 missed the $-0.08 estimate on $0.00 revenue.
−2.3% · S&P 500 +0.8%
Chemomab Therapeutics shares rose 32.0%, while the S&P 500 fell 0.1%.
+32.0%, the year's best day · S&P 500 −0.1%
EPS of $-0.27 missed the $-0.08 estimate on $0.00 revenue.
+10.0% · S&P 500 +0.2%
Chemomab Therapeutics closed at its highest level of the year, 6.0% above where the year started.
+3.7% · S&P 500 +1.0%
Chemomab Therapeutics shares fell 26.1%, while the S&P 500 fell 0.2%.
−26.1% · S&P 500 −0.2%
Chemomab Therapeutics closed at its lowest level of the year, 62.5% below where the year started.
−2.9% · S&P 500 +0.7%
Where it ended: a close of $1.35 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 23, 2026 (EPS est. $-0.04).
Nothing in the past 12 months.
All CMMB analyst actionsNothing in the past 12 months.
All CMMB dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CMMB and SPY from Benzinga historical bars. Not investment advice.
